Purpose Drug resistance presents a major obstacle for the treatment of some patients with chronic myeloid leukemia (CML). Pro-apoptotic ceramide mediates imatinib-induced apoptosis, and metabolism of ceramide by glucosylceramide synthase (GCS) activity, converting ceramide to glucosyl ceramide, might contribute to imatinib resistance. In this study, we investigated the role of ceramide metabolism by GCS in the regulation of imatinib-induced apoptosis in drug-sensitive and drug-resistant K562 and K562/IMA-0.2 and K562/IMA-1 human CML cells, which exhibit about 2.3-and 19-fold imatinib resistance, respectively. Methods Cytotoxic eVects of PDMP and imatinib were determined by XTT cell proliferation assay. Expression levels of GCS were determined by RT-PCR and western blot. Intracellular ceramide levels were determined by LC-MS. Cell viability analyses was conducted by Trypan blue dye exclusion assay. Cell cycle and apoptosis analyses were examined by Xow cytometry. Results We Wrst showed that mRNA and protein levels of GCS are increased in drug-resistant K562/IMA as compared to sensitive K562 cells. Next, forced expression of GCS in sensitive K562 cells conferred resistance to imatinib-induced apoptosis. In reciprocal experiments, targeting GCS using its known inhibitor, PDMP, enhanced ceramide accumulation and increased cell death in response to imatinib in K562/IMA cells. Conclusion Our data suggest the involvement of GCS in resistance to imatinib-induced apoptosis, and that targeting GCS by PDMP increased imatinib-induced cell death in drug-sensitive and drug-resistant K562 cells via enhancing ceramide accumulation.
Introduction
A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib, which has shown striking activity in the chronic phase and the accelerated phase, but less so in the blast phase of the disease (Buchdunger et al. 1996) . Despite high rates of hematologic and cytogenetic responses to therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of patients with CML (Deininger 2005; Hegedus et al. 2002; Krystal 2001; Koca and Haznedaroglu 2005; Walz and Sattler 2006) .
Resistance to anticancer agents can be explained by a number of mechanisms including decreased uptake, increased detoxiWcation, and alteration of target proteins or increased excretion. Even if anticancer drugs reach their sites of action, by passing drug eZux system of the cells, some cells still survive via the inhibition of pro-apoptotic signaling (Robertson et al. 1993 ). It has been well known that multidrug-resistant (MDR) cells show cross-resistance not only to anticancer agents but also to pro-apoptotic stresses including tumor necrosis factor , irradiation, antiFas antibody cross-linking, and serum starvation (Bradshaw and Arceci 1998). These suggest the possibility that dysregulation of apoptotic signaling plays a very important role in MDR (Hale et al. 1996) .
Sphingolipids are a family of membrane lipids with important roles not only in the regulation of the Xuidity and sub-domain structure of the lipid bilayer but also in many aspects of cell biology, from inXammatory responses through cell proliferation and apoptosis to cell migration and senescence . Many sphingolipid-regulated functions have signiWcant and speciWc links to various aspects of cancer initiation, progression, and response to anticancer treatments. Ceramide, an eVector molecule in apoptotic signaling, plays a principal role in the nature of cellular response to anticancer therapies and other stress-causing agonists (Hannun and Obeid 2002; Kolesnick and Kronke 1998) . The levels of intracellular pro-apoptotic ceramide were shown to be increased by anticancer drugs and stresses in cancer cells (Hannun 1996; Okazaki et al. 1998; Sawai et al. 1997) . It was also shown previously by diVerent groups that increased ceramide levels enhance the eYcacy of vinblastine , Adriamycin, daunorubicin, actinomycin D (Bose et al. 1995; Dbaibo et al. 1998; Liu et al. 1999) , and taxol (Myrick et al. 1999) .
On the other hand, alterations of the accumulation of ceramide via its increased metabolism to glucosylceramide (GlcCer) by glucosyceramide synthase (GCS) are a characteristic of various MDR cancer cells of colon, breast, ovarian, and epithelioid carcinomas Lavie et al. 1996; Nicholson et al. 1999 ). Lucci and co-workers showed that GlcCer levels are elevated in tumor specimens from patients with breast cancer and melanoma who demonstrated poor response to chemotherapy (Lucci et al. 1998) . The enzyme GCS transfers glucose from UDP-glucose to ceramide and produces GlcCer. GCS appears to have important functions over cell growth and apoptosis. It was shown that GlcCer induces tumor growth (Perales et al. 1998 ) and cell proliferation (Marsh et al. 1995) while inhibition of GCS results in cell death, eVect, inhibition of cell division (Kyogashima et al. 1996) , and reduction of metastasis (Inokuchi et al. 1990 ). However, involvement of increased ceramide metabolism by GCS in the regulation of imatinib-induced apoptosis and/or resistance in CML has not been reported previously.
In our previous study, we reported that increased generation of ceramide mediates imatinib-induced apoptosis, and overexpression of sphingosine kinase 1 (SK1) results in imatinib resistance in K562 cells via modulation of ceramide/S1P rheostat (Baran et al. 2007 ). Since glycosylation of ceramide by GCS emerges as a novel mechanism of drug resistance (Liu et al. , 2000 Kok et al. 2000) , we hypothesized that targeting GCS might be a novel strategy to overcome resistance to imatinib-induced cell death via restoring ceramide accumulation in CML cells.
In this study, our goal was to identify the role of ceramide metabolism by GCS in imatinib resistance, and to explore whether targeting GCS using its known inhibitor, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), presents a novel approach to reverse drug resistance in human K562 CML cells. Our data suggested that GCS expression at both mRNA and protein levels was increased signiWcantly in drug-resistant K562/IMA-0.2 and K562/IMA-1 cells as compared to parental and drug-sensitive K562 cells. Importantly, while forced expression of GCS inhibited imatinib-induced cell death in sensitive K562 cells, targeting GCS by PDMP in drug-resistant K562/IMA cells increased apoptosis in response to imatinib, which was consistent with elevation of endogenous ceramide levels, measured by Lipidomics. Thus, these data indicate that increased metabolism of ceramide by GCS is involved in the inhibition of imaitnib-induced cell death, and that targeting GCS by PDMP partially reverses drug resistance in K562/IMA cells via elevation of pro-apoptotic ceramide accumulation.
Materials and methods

Cell lines and culture conditions
The Philadelphia (Ph) chromosome-positive K562 human CML cells were obtained from German Collection of Microorganisms and Cell Cultures and maintained in RPMI 1640 growth medium containing 10% fetal bovine serum and 1% penicillin-streptomycin (Invitrogen, USA) at 37°C in 5% CO 2 .
Selection of imatinib-resistant K562 cells
We generated imatinib-resistant sublines of K562 cells that could grow in the presence of 0.2 (K562/IMA-0.2) and 1 M (K562/IMA-1) imatinib.
Measurement of cell growth by XTT assay
The IC50 values (drug concentration that inhibits cell growth by 50%) of imatinib and PDMP were determined by XTT cell proliferation assay. In short, 2 £ 10 4 cells/well were seeded into 96-well plates containing 100 l of the full medium with increasing concentrations of imatinib and PDMP and then incubated at 37°C in 5% CO 2 for 72 h. Then, the cells were treated with 50 l XTT for 4 h, and the plates were read under 492-nm wavelengths by ELISA reader (Thermo Electron Corporation Multiskan Spectrum,Vantaa, Finland) (Piskin et al. 2007 ).
Measurement of endogenous ceramide levels by lipidomics
The cellular levels of endogenous ceramides were measured using high performance liquid chromatography/mass spectrometry (LC/MS) as described previously (Koybasi et al. 2004) . In short, after cells were collected by centrifugation, lipids were extracted directly from cell pellets, and the levels of sphingolipids and inorganic phosphate (Pi) levels in the same extracts were measured as described (Koybasi et al. 2004) . The levels of ceramides were normalized to Pi concentrations.
Plasmids and transfections pcDNA3.1 and pcDNA3.1/GCS plasmids were obtained from Invitrogen, USA. Transfection of human CML cells was performed using an EVectene transfection kit (Qiagen) as described by the manufacturer.
Detection of human GCS mRNA by RT-PCR
Total RNA was extracted using Rneasy RNA isolation kit (Qiagen) as described by the manufacturer. Using reverse transcriptase (Promega), 1 g of total RNA was reverse transcribed. After 1 h incubation at 50°C, the reactions were stopped by 95°C heating for 5 min. The resulting total cDNA was then used in PCR to measure the mRNA levels of GCS and beta-actin. The mRNA levels of beta-actin were used as internal control (Ogretmen et al. 2001 ). The primer sequences and PCR conditions were as follows: GCS-forward (5ЈATGACAGAAAAAGTAGGCT3Ј),GC S-reverse (5Ј-GGACACCCCTGAG TGGAA-3Ј); and beta-actin-forward (5Ј-CAGAGCAAGAGAGGCATCCT-3Ј), beta-actin-reverse (5Ј-TTGAAGGTCTCA AACATG AT-3Ј). Using these primers, 1 l of the reverse transcriptase reaction was ampliWed for 35 cycles (94°C, 1 min; 55°C, 2 min; 72°C, 2 min) using Taq DNA polymerase (Qiagen), and their levels were normalized to that of betaactin as described previously (Ogretmen et al. 2001 ).
Western blot analysis
The protein levels of GCS and beta-actin were detected by Western blot analysis (Sultan et al. 2006) . In short, total proteins (50 g/lane) were separated by 5-15% SDS-PAGE (Bio-Rad) and blotted onto an Immobilon membrane, and GCS and beta-actin proteins were detected using 1 g/ml of rabbit polyclonal anti-GCS or beta-actin (Santa Cruz Biotechnology) antibodies, and peroxidase-conjugated secondary anti-rabbit antibody (1:2,500). The proteins were visualized using the ECL protein detection kit (Amersham Pharmacia Biotech) as described by the manufacturer.
Detection of cell death
EVects of imatinib on cell death in the presence and/or absence of GCS overexpression, or PDMP treatment in K562 versus K562/IMA-0.2 or K562/IMA-1 cells were examined using trypan blue exclusion and/or Xow cytometry, as we described previously.
Results
One of the mechanisms of resistance to imatinib-induced cell death involves the overexpression of GCS We previously explored cytotoxic eVect of imatinib on imatinib-sensitive and imatinib-resistant K562 cells (Baran et al. 2007 ). The results revealed that K562/IMA-0.2 and K562/IMA-1 cells showed 2.3-to 19-fold resistance to imatinib, as compared to sensitive cells. The IC 50 values of imatinib for K562, K562/IMA-0.2, and K562/IMA-1 cells were 240, 565, and 4,600 nM, respectively (Baran et al. 2007 ). To examine whether mechanisms by which K562/ IMA-0.2 and K562/IMA-1 cells acquired resistance to imatinib-induced apoptosis involves the overexpression of GCS, the mRNA levels of GCS in these cells as compared to their parental sensitive controls were examined by RT-PCR (Fig. 1a) and protein levels were detected by western blotting (Fig. 1b) . The data in Fig. 1a showed that there were 1.85-fold increases in expression levels of GCS in K562/IMA-1 cells as compared to parental sensitive cells. Western blot analysis also conWrmed overexpression of GCS in protein levels (Fig. 1b) . Beta-actin levels were used as loading controls in Western blotting (Fig. 1b, lower  panel, lanes 1-3) .
Role of GCS in resistance to imatinib-induced apoptosis As shown in Fig. 2a , in GCS transfected K562 cells, imatinib signiWcantly prevented cell death (Fig. 2a) . SpeciWcally, treatment with 200 and 500 nM imatinib resulted in about 30 and 55% cell death in response to control vector in K562 cells. On the other hand, in GCS transfected K562 cells, 200 and 500 nM imatinib caused only around 10 and 25% growth inhibition, respectively (Fig. 2a) . The expression levels of GCS in control (vector-transfected) and GCS transfected human K562 cells were conWrmed by RT-PCR, and beta-actin levels were used as loading controls (Fig. 2b , lanes 2-3, and 4-5, respectively). These data, therefore, demonstrate an important role for GCS in resistance to imatinib-induced cell death in K562 cells.
Analyses of ceramide levels in human CML cells in response to PDMP in the absence or presence of imatinib
The levels of endogenous ceramide in parental and imatinib-resistant K562 cells, treated with PDMP, in the absence or presence of imatinib (48 h), were measured by LC/MS (Fig. 3a-c) . The intracellular levels of ceramides were increased about 2-to 8-fold in K562 and K562/IMA-0.2 and about 2-to 4-fold K562/IMA-1 cells treated with imatinib (0.2, 0.5 and 2 M, respectively). In PDMP exposed K562 cells, the ceramide levels were slightly increased (about 1-to 5-fold). Importantly, in all three K562 sublines, combination of PDMP with imatinib treatment caused signiWcant increases in C 18 -ceramide levels (35-, 11-, and 6-fold, respectively) in K562, K562/IMA-0.2, and K562/IMA-1 cells, respectively (Fig. 3a-c) . Taken together, these data suggest that imatinib induces C 18 -ceramide accumulation, and targeting GCS using PDMP further enhances its accumulation in K562, K562/IMA-0.2, and K562/IMA-1 cells.
Cell viability analyses of parental and imatinib-resistant K562 cells exposed to GCS inhibitor, PDMP To examine the involvement of GCS in resistance to imatinib-induced cell death, parental and K562/IMA-0.2 cells were exposed to PDMP, in the absence or presence of imatinib. K562 cells exposed to 10 M PDMP in the presence of 500 nM imatinib resulted in about 90% cell death, while 500 nM imatinib, by itself, caused around only 60% of growth inhibition (Fig. 4a) . As shown in Fig. 4b , K562/IMA-0.2 cells exposed to 10 M PDMP in the presence of 500 nM imatinib resulted in about 35% cell death. Treatment of K562/IMA-0.2 cells with 500 nM imatinib, by itself, caused around 8% growth inhibition (Fig. 4b) . Ten M PDMP did not have any eVect on K562 or K562/ IMA-0.2 cells. These data showed that combination therapy of imatinib and PDMP together resulted in higher number of cells in apoptosis as compared to only imatinib exposed cells.
Cell cycle proWles of human CML cells exposed to PDMP in the absence or presence of imatinib
In addition to cell viability analyses, the cell cycle proWles of K562 and K562/IMA-0.2 cells, exposed to PDMP, in the absence or presence of imatinib, were examined for 6, 24, and 48 h by Xow cytometry. The data revealed that exposure to imatinib (200 nM, 6 h) did not cause apoptosis in The data for 48 h showed that exposure to imatinib (200 nM, 48 h) resulted in 9 and 0% apoptosis in parental (Fig. 5a ) and resistant K562/IMA-0.2 (Fig. 5c ) cells, respectively. Imatinib treatment in K562 cells resulted in an increase in G1 and a decrease in G2 and S phases (Fig. 5a ). K562 cells exposed to 20 M PDMP and 200 and 500 nM imatinib (48 h) resulted in 20 and 40% apoptosis, respectively (Fig. 5b) . PDMP and imatinib treatment also resulted in an increase in G1-phase, no change in S-phase, and a signiWcant decrease in G2 phase in K562 cells. In case of K562/IMA-0.2 cells, treatment with 20 M PDMP 200 and 500 nM imatinib (48 h) resulted in 14 and 22% apoptosis, respectively (Fig. 5d) while there was no cell in apoptosis in only imatinib applied resistant cells.
Taken together all these data showed that imatinib with the combination of PDMP has much more apoptotic eVect on both sensitive and resistant cells. This combination therapy has started to be eVective after 24 h of application. Besides induction of apoptosis, PDMP and imatinib treatment also resulted in cell cycle arrest at G1 phase in K562 cells.
XTT cell proliferation assay in human CML cells exposed to PDMP in the absence or presence of imatinib
The IC 50 values of imatinib and the combination therapy of PDMP and imatinib together in K562/IMA-1 cells were determined. The IC 50 values of imatinib and combination therapy of PDMP and imatinib were 4,600 and 1,100 nM for K562/IMA-1 cells, respectively (Fig. 6 ). As shown in Fig. 6 , K562/IMA-1 cells, exposed to PDMP and imatinib, expressed about 4-fold more sensitivity, as compared to only imatinib-treated counterparts.
Discussion
In order to generate imatinib-resistant sub-lines of human CML cell line, K562 were cultured in the presence of gradually increasing concentrations (0.05-1 M) of imatinib over a period of 24 months. However, rare Ph-positive K562 cells were observed, which were unaVected by concentrations of imatinib that suppress the proliferation of most CML cells. These sub-lines with diVerential sensitivity to imatinib were generated from imatinib-sensitive BCR-ABL-positive human CML cells.
The Wrst important observation from this study was the overall diYculty in generating resistant sub-lines from the parental sensitive cells. Rare survivors could be obtained from high numbers of cells, even when subjected to a gradual exposure to imatinib. These results emphasized the high eYcacy and speciWcity of imatinib in the treatment of BCR-ABL-positive cells.
Similar approach has been used in various studies to derive imatinib resistance starting with Ph-positive cell lines previously, including AR230, LAMA84, and K562 cell lines (Mahon et al. 2000) . Mahon and co-workers were able to grow K562 cells up to the presence of 0.6 M imatinib concentrations. In this study, K562 cells were able to be grown up to 1 M.
Drug resistance could result from elevated levels of the various components of the cell such as GlcCer Lucci et al. 1998) . Analysis of human tumor specimens revealed elevated GlcCer levels in patients who failed conventional chemotherapy, but GlcCer levels were low in those who responded to treatment (Lucci et al. 1998) . Support for the involvement of GCS in drug resistance came from transfection experiments, which showed that overexpression of the enzyme resulted in increased resistance to Adriamycin in drug-sensitive MCF-7 tumor cells . These results can be interpreted in the sense that MDR tumor cells display an enhanced activity of GCS, which results in accumulation of GlcCer and metabolic removal of ceramide from the sphingolipid pool. In agreement with the previous studies, GCS overexpression has been observed in imatinib-resistant human CML cells, K562/IMA-0.2 and K562/IMA-1, as compared to parental sensitive counterparts. Our previous data revealed an important role for SK1/ S1P signaling as a major mechanism of imatinib resistance by decreasing ceramide/S1P ratio in CML cells (Baran et al. 2007 ). The role of SK1/S1P in drug resistance in CML was also conWrmed by independent studies (Bonhoure et al. 2008; Li et al. 2007 ). In the current study, we increased the intracellular concentrations of ceramide via inhibition of GCS and examined the possibility of enhancing apoptosis in response to imatinib in both sensitive and resistant cells. GCS inhibitors have been found to raise cellular ceramide levels by blocking its conversion into GlcCer and to induce apoptosis (Nicholson et al. 1999; Spinedi et al. 1998) . It has previously been demonstrated that PDMP sensitizes murine neuroblastoma cells to Taxol and Vincristine (Sietsma et al. 2000) . In this study, PDMPinduced chemo sensitization was investigated in two imatinib-resistant human CML cells. In parallel with the previous data, LC/MS analyses revealed that impairment of ceramide glycosylation by PDMP increased intracellular ceramide levels. On the other hand, cell viability analyses by trypan blue dye exclusion assay and Flow cytometry and cell proliferation analyses by XTT assay also showed that PDMP in combination with imatinib resulted in higher numbers of cells in apoptosis as compared to only imatinib exposed cells. These Wndings demonstrate the ability to modulate ceramide metabolism should provide a new avenue by which drug sensitivity can be increased in multidrug-resistant cells.
In conclusion, these results show, for the Wrst time, that overexpression of GCS, via increased metabolism of ceramide via conversion to GlcCer, decreasing its cellular accumulation, is involved in the regulation of imatinib resistance in K562 cells, and that this resistance could be overcome, at least in part, by inhibition of GCS, which enhances ceramide accumulation in response to imatinib treatment.
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